# Full Reference List

> References — Formula1 Peptides — The full, numbered reference list behind every cited claim on Formula1 Peptides — BPC-157, TB-500, and KLOW.

**REFERENCES**

Every cited source behind the claims on this site, numbered as used in text.

## About this list

Every numbered citation used across Formula1 Peptides is listed below with its full source, year, and a link where available. Citations are shared across all three compound pages, so a single reference may support findings on more than one page.

## References

[1] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
[2] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[3] He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[4] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[5] Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10:1032-1037. https://pubmed.ncbi.nlm.nih.gov/15052688/
[6] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[7] Morris DC, et al. A dose-response study of thymosin β4 for the treatment of acute stroke. J Neurol Sci. 2014. https://pubmed.ncbi.nlm.nih.gov/25060418/
[8] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[9] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010. https://pubmed.ncbi.nlm.nih.gov/20536472/
[10] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[11] Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. https://pubmed.ncbi.nlm.nih.gov/15565145/
[12] Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. https://pubmed.ncbi.nlm.nih.gov/10469335/
[13] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[14] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[15] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/

---

Formula1 Peptides is an independent tissue-repair literature review, not a clinic, not a formulator, and not a substitute for reading the cited studies yourself.